Guy Boudreau
YOU?
Author Swipe
View article: Table of Contents
Table of Contents Open
View article: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM Open
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
View article: CJN volume 50 issue 3 Cover and Front matter
CJN volume 50 issue 3 Cover and Front matter Open
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
View article: Botox for Unremitting Chronic Migraine: Assessment of Muscle Function and Strength, Efficacy and Safety after More Than 10 Years of Continuous Treatment
Botox for Unremitting Chronic Migraine: Assessment of Muscle Function and Strength, Efficacy and Safety after More Than 10 Years of Continuous Treatment Open
Objectives: Our objectives were 3-fold: Assess the impact of the injection paradigms on muscle function and strength, assess the efficacy and safety over 10 years of repeated treatments every 3 months, identify risk factors maintaining chr…
View article: CJN volume 49 issue 4 Cover and Front matter
CJN volume 49 issue 4 Cover and Front matter Open
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
View article: Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis Open
Objective To assess the long‐term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (≥1, ≥2, and ≥3 TF medication categories) and never failed (preven…
View article: OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study
OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study Open
Background: PREDICT was a Canadian, multicenter, prospective, observational study in adults naïve to onabotulinumtoxinA treatment for chronic migraine (CM). We descriptively assess health resource utilization, work productivity, and acute …
View article: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study
OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study Open
Background: The PREDICT study assessed real-world, long-term health-related quality of life in adults with chronic migraine (CM) receiving onabotulinumtoxinA. Methods: Canadian, multicenter, prospective, observational study in adults naïve…
View article: Treatment of Chronic Migraine with Erenumab Alone or as an Add on Therapy: A Real-World Observational Study
Treatment of Chronic Migraine with Erenumab Alone or as an Add on Therapy: A Real-World Observational Study Open
Objectives: Chronic migraineurs having failed more than 3 preventive drugs were treated with Erenumab alone or as an add on therapy, we assessed the frequency of monthly migraine days, the value of an add on therapy, and all adverse events…
View article: P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT
P.011 OnabotulinumtoxinA, quality of life, health resource utilization, and work productivity in chronic migraine: interim results from PREDICT Open
Background: We assessed long-term health-related quality of life (HRQoL) and functioning in adults receiving onabotulinumtoxinA for CM. Methods: Interim analysis of multicentre, prospective, observational study in adults naïve to botulinum…
View article: Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Early onset of efficacy with erenumab in patients with episodic and chronic migraine Open
Erenumab showed early onset of efficacy with separation from placebo within the first week of treatment in both chronic and episodic migraine patients.
View article: Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety
Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety Open
Prophylactic onabotulinumtoxinA was well tolerated in patients with chronic migraine and comorbid depression, and was effective in reducing headache frequency, impact, and related disability, which led to statistically significant improvem…